A Phase II Study of Combination Chemotherapy in Advanced Ovarian Carcinoma with Cisplatin and Cyclophosphamide plus Reduced Glutathione as Potential Protective Agent against Cisplatin Toxicity
| Autor: | Maria Cristina Locatelli, Adelaide D'Antona, Antonello Corbo, Paola Venturino, Michele Tedeschi, Gino Luporini, Rosario Carcione, Roberto Labianca, Maria Vinci |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Cancer Research Cyclophosphamide Phases of clinical research Pharmacology Kidney Drug Administration Schedule 030218 nuclear medicine & medical imaging Nephrotoxicity 03 medical and health sciences 0302 clinical medicine Therapeutic index Ovarian carcinoma Antineoplastic Combined Chemotherapy Protocols Humans Medicine Aged Ovarian Neoplasms Cisplatin business.industry Combination chemotherapy General Medicine Middle Aged Glutathione Oncology 030220 oncology & carcinogenesis Toxicity Female business medicine.drug |
| Zdroj: | Tumori Journal. 79:37-39 |
| ISSN: | 2038-2529 0300-8916 |
| DOI: | 10.1177/030089169307900108 |
| Popis: | Aims and Backgroud The clinical use of cisplatin (CDDP)„ one of the most active agents in advanced ovarian cancer, is limited by nephrotoxicity and cumulative neurotoxicity. In preclinical studies, reduced glutathione (GSH) demonstrated a protective action against CDDP nephrotoxicity. We treated 20 patients with advanced ovarian carcinoma, with polichemotherapy containing CDDP + GSH, to assess the protective action of GSH against CDDP nephrotoxicity. Methods Between January 1988 and December 1989, 20 patients, with advanced ovarian carcinoma (St. III-IV-FIGO), not pretreated received CDDP: 45 mg/m2 i.v., on day 1-2, + cyclophosphamide (CPA): 900 mg/m2 i.v. on day 2 + GSH 2500 mg i.v. in normal saline 100 ml (in 15 min), before CDDP, every 21-28 days. Results A pathologic complete response rate (PCR) of 55 % (11/20) was observed (7/14 patients with bulky disease). Median survival was 26.5 months and 5 patients were still alive and disease free at 35 months. Toxicity was limited, without any case of nephrotoxicity. Conclusions On the basis of our previous experience with the same regimen without GSH, this study suggests that also in the clinical setting, GSH has no negative interference on CDDP activity and that GSH might improve the therapeutic index of CDDP. However, our data need to be confirmed by large randomized clinical studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|